Department of Pharmacy, The 309th Hospital of PLA, Beijing 100019, China.
School of Pharmacy and Bioengineering, Chongqing University of Technology, Chongqing 400054, China; Department of Pharmacy, Xinan Hospital, Third Military Medical University, Chongqing 400038, China.
Acta Biomater. 2019 Oct 1;97:461-473. doi: 10.1016/j.actbio.2019.07.033. Epub 2019 Jul 22.
Nanomedicine with programmed drug release can give full play to the synergistic effect of multi-component system in complicated tumor environment. However, the construction of these programmed drug delivery systems often depends on the sophisticated materials design and synthesis. In this study, we successfully designed an indomethacin (IND)-mediated ternary complex system based on a PEG cleavable polyethyleneimine (PEI), indomethacin (IND) and benzene ring containing chemotherapeutic drugs (such as paclitaxel (PTX), doxorubicin and docetaxel). Based on the difference of hydrophobicity in these components, these components were one-pot self-assembled into drug-loaded IND mediated PEGylation cleavable nanoassemblies (IPCNs) in multilayer structure. In drug-loaded IPCNs, PEG fragments, PEI/IND, and chemotherapeutic drug were respectively distributed from the out layer to core of nanomedicine. When drug-loaded IPCNs reached tumor site through EPR effect, the PEG fragment would firstly responsively release to the acidic tumor microenvironment to expose the intermediate layer of drug-loaded IPCNs that composed by mixture of PEI and IND for increasing the surface potential to promote the uptake by tumor cells. After entering cells, IND would be released faster than chemotherapeutic drug encapsulated in core to efficiently inhibit the expression of multidrug resistance protein 1 to reverse MDR of tumor cells before chemotherapeutic drug releasing. Contributed by the staged responsively releasing of PEG fragments, IND and encapsulated chemotherapeutic drug, the drug-loaded IPCNs exhibited a superior antitumor efficacy against A549/MDR tumor cells both in vitro and in vivo. STATEMENT OF SIGNIFICANCE: The way to develop programmed released drug delivery system is commonly relied on complicated material design and synthesis. Herein, under the computer-assist design, we successfully designed a ternary complex derived from indomethacin (IND), paclitaxel (PTX) and a pH-responsive PEGylated polyethyleneimine (PEG-s-PEI), and employed this ternary complex to successfully prepare a high drug loading and multilayer structured nanomedicine of PTX (PTX IPCNs). Contribute by the different location of PTX, IND and PEG-s-PEI in PTX IPCNs, PEG fragments, IND and PTX molecules could programmed release after reaching tumor for perfectly realizing the synergistic anti-tumor effect of tumor targeting, reversal of MDR and chemotherapy. Based on a fusion of these multiple mechanisms, PTX IPCNs showed a superior antitumor efficacy in mice loading A549/MDR tumor.
纳米医学中的药物控释可以充分发挥多组分系统在复杂肿瘤环境中的协同作用。然而,这些程序药物输送系统的构建通常依赖于复杂的材料设计和合成。在本研究中,我们成功设计了一种基于可切割聚乙二醇的聚乙烯亚胺(PEI)、吲哚美辛(IND)和含苯环化疗药物(如紫杉醇(PTX)、阿霉素和多西他赛)的吲哚美辛介导的三元复合体系。基于这些成分的疏水性差异,这些成分在一锅法中自组装成具有多层结构的载药 IND 介导的聚乙二醇化可切割纳米组装体(IPCNs)。在载药 IPCNs 中,PEG 片段、PEI/IND 和化疗药物分别从纳米医学的外层分布到核心。当载药 IPCNs 通过 EPR 效应到达肿瘤部位时,PEG 片段首先响应酸性肿瘤微环境释放,暴露出由 PEI 和 IND 组成的载药 IPCNs 的中间层,以增加表面电位,促进肿瘤细胞摄取。进入细胞后,IND 比包封在核心中的化疗药物更快释放,以有效抑制多药耐药蛋白 1 的表达,在化疗药物释放前逆转肿瘤细胞的 MDR。由于 PEG 片段、IND 和包封的化疗药物的阶段性响应释放,载药 IPCNs 在体外和体内对 A549/MDR 肿瘤细胞均表现出优异的抗肿瘤疗效。意义声明:开发程序释放药物递送系统的方法通常依赖于复杂的材料设计和合成。在这里,在计算机辅助设计下,我们成功设计了一种源自吲哚美辛(IND)、紫杉醇(PTX)和 pH 响应聚乙二醇化聚乙烯亚胺(PEG-s-PEI)的三元复合物,并采用该三元复合物成功制备了一种高载药量和多层结构的紫杉醇纳米药物(PTX IPCNs)。由于 PTX、IND 和 PEG-s-PEI 在 PTX IPCNs 中的不同位置,PEG 片段、IND 和 PTX 分子在到达肿瘤后可以进行程序释放,从而完美地实现了肿瘤靶向、MDR 逆转和化疗的协同抗肿瘤作用。基于这些多种机制的融合,PTX IPCNs 在载有 A549/MDR 肿瘤的小鼠中表现出优异的抗肿瘤疗效。